Oren Josh Becher

This study identifies a combinatorial strategy using ALK2 inhibitors and statins to target metabolic dependencies in diffuse midline glioma.

This study identifies ADAR as a key mediator of immune evasion in H3K27M+ pediatric gliomas and shows that ATRA can induce ADAR degradation, enhancing antiviral responses and tumor immunogenicity.

This study evaluates combination therapy of CDK4/6 and MEK inhibitors in DMG models, finding survival benefits in GEM but not PDX models.

This study identifies CD155 as a key regulator of tumor growth and immune evasion in diffuse midline glioma, showing that targeting CD155 or its downstream target FOXM1 can inhibit tumor progression.